Results 121 to 130 of about 8,510 (199)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer. [PDF]

, 2017
Jalal, Shadia I., Mamdani, Hirva
core   +1 more source

New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment

Discover Oncology
To explore the presentation and control of CNS adverse reactions in patients with ALK-positive NSCLC treated with lorlatinib. This study includes a retrospective case report from Sir Run Run Shaw Hospital on a lorlatinib-treated patient with CNS adverse ...
Fanfan Chu, Wenxi Zhang, Hong Hu
doaj   +1 more source

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

JTO Clinical and Research Reports
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting doses
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD   +18 more
doaj   +1 more source

Case report: Dissolving carotid plaque associated to Lorlatinib-related dyslipidemia

Frontiers in Oncology
We present a case with prolonged Lorlatinib-related dyslipidemia causing internal carotid artery stenosis, putting the patient at risk of cerebrovascular events.
Lukas Mayer-Suess, Michael Knoflach, Michael Knoflach, Andreas Pircher, Stefan Kiechl, Stefan Kiechl, Christoph Schmidauer, Eva Hametner   +7 more
doaj   +1 more source

Lorlatinib [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Resistance to anaplastic lymphoma kinase inhibitors: Knowing the enemy is half the battle won [PDF]

, 2020
Bironzo, P., Reale, M. L., Scagliotti, G. V., Tabbo, F.   +3 more
core   +1 more source

Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel. [PDF]

Future Oncol
Ardizzoni A, Cortinovis D, Gori B, Nuzzo A, Pasello G, de Marinis F.   +5 more
europepmc   +1 more source

Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis. [PDF]

Front Oncol
Li Y, Wen Y, Zhang W, Zhao Y, Zhou L, Zeng X, Kang X, Li L.   +7 more
europepmc   +1 more source

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial. [PDF]

Future Oncol
Ahn MJ, Delmonte A, Ghosh S, Hochmair M, Yang TY, Yang JC, Han JY, Hansen KH, Wu Y, Wan Y, Lin HM, Kretz J, Hupf B, Kurec AM, Churchill EN, Fram RJ, Cabasag CJ, Goriya V, Zhao Y, Campelo MRG.   +19 more
europepmc   +1 more source

Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system. [PDF]

Front Neurol
Wei X, Lai Q, Zheng L.
europepmc   +1 more source